国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Latest

Chinese researchers: HCQ ineffective in treating COVID-19

By ZHOU WENTING in Shanghai | chinadaily.com.cn | Updated: 2020-05-18 19:48
Share
Share - WeChat

The latest clinical trial by Chinese researchers has found that hydroxychloroquine (HCQ) is not effective in treating patients who are mildly and moderately ill with COVID-19, experts announced at a news briefing on Monday.

The paper about the study was published on the website of the British Medical Journal on May 15. It the world's first multi-center study of its kind to be released on a medical journal.

The randomized controlled clinical trial was conducted at 16 Chinese hospitals designated as COVID-19 treatment centers.

HCQ, an antimalaria and anti-inflammatory drug, has been used in several countries to treat COVID-19 and was recommended by the United States government as a viable treatment option.

"Compared with standard treatments, the use of HCQ for COVID-19 patients did not provide extra benefits, and there exists a higher incidence rate of adverse drug reactions," said Xie Qing, director of the infectious disease department at Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, which led the multi-center research.

She said that the result of the trial did not support the use of the drug, which was previously proven to be effective in inhibiting the novel coronavirus through in vitro tests. It was subsequently approved for use on mildly and moderately ill patients by several countries, including France and the US.

The trial involved 150 patients who were randomly split into two groups. Half of the patients were treated according to the national treatment guidelines while the other half were given 1,200 milligrams of the drug for the first three days and 800 mg for the remaining days.

After 28 days of treatment, the rate of the virus turning negative was 85.4 percent for the first group and 81.3 percent for the one that received HCQ.

Researchers also pointed out that the rate of adverse drug reactions among the group given HCQ was 30 percent, higher than the other group which had just 9 percent. The adverse reactions were mainly diarrhea and vomiting.

Qu Jieming, Party secretary of Ruijin Hospital, said that the participants were included in the study after showing symptoms for a median of 16.6 days. He added that the research findings have provided an insight into the potential conduct of studies in the future to determine if the drug would be effective if used earlier on patients.

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
洞口县| 津市市| 陆良县| 晋宁县| 海口市| 潜江市| 宿迁市| 延边| 仁怀市| 鹤峰县| 大石桥市| 津南区| 广元市| 平和县| 马公市| 洛阳市| 寻甸| 湘阴县| 锡林浩特市| 重庆市| 界首市| 焉耆| 和平县| 平遥县| 信阳市| 神池县| 天全县| 体育| 文昌市| 黄大仙区| 兴国县| 通化市| 阳山县| 民丰县| 新巴尔虎左旗| 长阳| 休宁县| 和静县| 上饶市| 渭源县| 深泽县|